Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals in Zika Virus

Tuesday, July 26, 2016 Tropical Disease News
Email Print This Page Comment bookmark
Font : A-A+

Funding provided by the National Institute of Allergy and Infectious Diseases

SEATTLE, July 26, 2016 /PRNewswire/ -- Kineta, Inc., a biotechnology company focused on the translational development

of novel antiviral and immune modulating drugs announced today it has received funding to expand testing of our broad spectrum innate immune antivirals in Zika virus.  Supplemental funding for Zika testing is being provided by the National Institute of Allergy and Infectious Disease (NIAID) to evaluate lead broad spectrum antivirals in preclinical models of Zika virus infection. 

Logo -

Zika virus has been named as a global public health emergency by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).  "There is a critical need for therapeutics to combat emerging viruses like Zika that are creating a public health crisis across the globe," said Dr. Shawn Iadonato, Kineta CEO.  "We are eager to expand testing of our broad spectrum antivirals in Zika virus as they have shown compelling efficacy across other flaviviruses such as Dengue and West Nile and have the potential for long term development as a pan-flavivirus therapy." 

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs.  For more information on Kineta, Inc. visit our website,

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta's plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy Email (206) 378-0400

To view the original version on PR Newswire, visit:

SOURCE Kineta, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store